E006 Ultrashort echo time magnetic resonance imaging of myelin and iron in Huntington’s disease (HD)
Year: 2024
Type: conference-paper
Abstract: Background Past studies have demonstrated extensive white and gray matter degeneration in Huntington’s Disease (HD), including demyelination and iron accumulation.1–4 Demyelination disrupts axonal transport, integrity, and structural plasticity,5–7 and plays a major role in HD.8–10 Iron accumulation contributes to neurodegeneration.11–13 However, myelin has an ultrashort T2, and is ’invisible’ with conventional MRI, which provides no quantitative information on iron. Aims We report a 3D Short TR Adiabatic Inversion Recovery UTE (STAIR-UTE) sequence for Myelin Proton Fraction (MPF) mapping,14 a UTE Quantitative Susceptibility Mapping (UTE-QSM) sequence for iron mapping,15 and a divided Subtracted Inversion Recovery (dSIR) sequence16 for high contrast imaging in HD. Methods The STAIR-UTE sequence included: FOV=220×220×240 mm³, matrix=92×92×80, resoltion=2.4×2.4×4.0 mm³, TE=0.032/1.2ms, TR/TI=154/67ms, bandwidth=125 kHz, 7.5 min. The UTE-QSM sequence included: FOV=220×220×160 mm³, matrix=220×220×80, resolution=1.0×1.0×2.0 mm³, TR=28ms, six-echo (TE=0.032,4.4,8.8,13.2,17.6,22ms), 7 min. The dSIR sequence included two inversion recovery FSE acquisitions with TIs of 400/600ms. Five HD patients and five controls were scheduled (four participants already scanned) for this feasibility study. Results/Outcome Figure 1 shows MPF maps that display myelin loss in white matter of the HD patient compared with the control. Figure 2 shows UTE-QSM maps. These show significant iron accumulation in putamen, globus pallidus, caudate, and external capsule of the HD patient compared with the control. Figure 3 shows dSIR images which depict abnormal structural changes in white matter of the HD patient and smaller globus pallidus, putamen and caudate nucleus compared with the control. Conclusion STAIR-UTE, UTE-QSM, and dSIR sequences can depict myelin loss, iron accumulation, and structural changes in HD patients. References Bartzokis, et al. Neurochem Res 2007;32:1655–64. Bohanna, et al. Brain Res Rev 2008;58:209–25. Kassubek, et al. CerebCortex 2005;15:846–53. Kloppel, et al. Neuroscience 2009;164:205–19. Waxman SG. ArchNeurol 1977;34(10):585–9. Filley, et al. Neurophysiol 2016;116(5):2093–104. Miller, et al. PNAS 2012;109:16480–5. Dean, et al. Neuroimage 2016;132:225–37. Bourbon-Teles, et al. J Neuroscience 2019;403:79–92. Casella, et al. J Huntington’s Dis 2020;9:303–20. Chen, et al. JNR 2019;97:467–79. Dominguez, et al. JNNP 2016;87:545–9. van Bergen, et al. AJNR 2016;37:789–96. Ma, et al. Radiology 2020;297:392–404. Jang, et al. Front Neurosci 2022;16:1033801. Ma, et al. QIMS 2023;13:7304–7337.
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4402374594